000			02148 a2200589 4500
005			20250514205314.0
264		0	_c20041207
008			200412s 0 0 eng d
022			_a0007-0920
024	7		_a10.1038/sj.bjc.6602190 _2doi
040			_aNLM _beng _cNLM
100	1		_aDeutsch, E
245	0	0	_aTyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. _h[electronic resource]
260			_bBritish journal of cancer _cNov 2004
300			_a1735-41 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzamides
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aDNA-Activated Protein Kinase
650	0	4	_aDNA-Binding Proteins _xantagonists & inhibitors
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aEnzyme Inhibitors _xtherapeutic use
650	0	4	_aFusion Proteins, bcr-abl
650	0	4	_aGene Expression Regulation, Leukemic
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aLeukemia, Erythroblastic, Acute _xdrug therapy
650	0	4	_aMice
650	0	4	_aMice, Nude
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aNuclear Proteins
650	0	4	_aPhosphorylation
650	0	4	_aPiperazines _xpharmacology
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins _xmetabolism
650	0	4	_aProto-Oncogene Proteins c-akt
650	0	4	_aPyrimidines _xpharmacology
650	0	4	_aTumor Cells, Cultured
650	0	4	_aTyrphostins _xtherapeutic use
700	1		_aMaggiorella, L
700	1		_aWen, B
700	1		_aBonnet, M L
700	1		_aKhanfir, K
700	1		_aFrascogna, V
700	1		_aTurhan, A G
700	1		_aBourhis, J
773	0		_tBritish journal of cancer _gvol. 91 _gno. 9 _gp. 1735-41
856	4	0	_uhttps://doi.org/10.1038/sj.bjc.6602190 _zAvailable from publisher's website
999			_c15184377 _d15184377